Clinico-pathologic Profiles and 5-year Survival Rate of 2209 Patients with Invasive Cancer of the Uterine Cervix / 대한산부인과학회잡지

ABSTRACT

OBJECTIVE: This study was performed to investigate the clinico-pathologic characteristics and to analyze the 5-year survival rate and prognostic factors for invasive cancer of the uterine cervix. METHODS: From May 1982 to October 2000, 2209 patients with invasive cancer of the uterine cervix were diagnosed and treated at Samsung Cheil Hospital. In this retrospective study, we studied the clinico- pathologic characteristics (age, resident area, delivery type, FIGO stage, histologic type, nodal metastasis, lymph-vascular space invasion, endometrial extension), treatment modalities and 5-year survival rate. RESULTS: The mean age was 50.3 years (24-85) and the median age was 50.0 years old. The most common subsets of patients were found in the group of FIGO stage I b (41.9%) and age between 41 and 50 (30.0%). Surgery was the main treatment in stage I a, I b, II a and radiation in stage II b or more. Pelvic and para-aortic nodal metastasis were surgically identified in 1.9% and 0% of stage I a, 18.1% and 4.4% of stage I b, 22.6% and 5.7% of stage II a, 51.4% and 17.1% of stage II b, 14.3% and 0% of stage III/IV. Overall 5-year survival rate was 85.7%; stage I a (93.9%), I b (91.5%), II a (80.7%), II b (68.5%), III/IV (53.7%). The 5-year survival rate according to pelvic lymph node status in surgically confirmed patients were 95.4% in negative patients and 78.1% in positive patients respectively (P=0.0000). 5-year survival rate was significantly different according to age (P=0.0000), FIGO stage (P=0.0000), lymph-vascular space invasion (P=0.0001), endometrial extension (P=0.0199), pelvic (P=0.0000) and para-aortic nodal metastasis (P=0.0000). However, resident area, delivery type, histologic type did not show any significant differences in survival. CONCLUSION: Overall 5-year survival rate of 2209 patients with invasive cancer of the cervix who were diagnosed at Samsung Cheil Hospital from May 1982 to October 2000 was 85.7%. Five-year survival rate was different according to age, FIGO stage, lymph-vascular space invasion, endometrial extension, pelvic and para-aortic nodal metastasis.